Gastrointestinal Cancer | Specialty

Dr. O'Reilly on the NEOLAP Study in Locally Advanced Pancreatic Cancer

October 11th 2019

Eileen O'Reilly, MD, discusses the phase II NEOLAP study which showed that more patients with locally advanced pancreatic cancer were able to undergo surgical resection following induction chemotherapy with gemcitabine and nab-paclitaxel or sequential FOLFIRINOX.

Next Steps for Immunoscore in Oncology

October 10th 2019

Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses next steps with Immunoscore in oncology.

Liver-Directed Therapies Enhance Treatment Landscape for Metastatic NETs

October 9th 2019

Patients with neuroendocrine tumors that have metastasized to the liver derive clinical benefit from locoregional therapies, but treatment guidelines for employing these strategies must be more fully developed.

FDA Awards Research Grants for 12 Rare Diseases, Including GIST, AML, and Brain Tumors

October 9th 2019

The FDA has awarded 12 new research grants that together total more than $15 million, to enhance the development of medical products for patients with rare diseases, including acute myeloid leukemia and gastrointestinal stromal tumor, among others.

Dr. O'Reilly on Agents in Development in Advanced Pancreatic Cancer

October 8th 2019

Eileen O'Reilly, MD, associate director for clinical research and medical oncologist at Memorial Sloan Kettering Cancer Center, discusses agents in development in advanced pancreatic cancer.

ATOMIC Looks at Immunotherapy in Early-Stage dMMR Colon Cancer

October 7th 2019

Investigators are seeking to determine whether immunotherapy that has been effective in metastatic colon cancers with deficient DNA mismatch repair can be applied to earlier-stage disease, specifically, nonmetastatic stage III colon cancer.

Dr. Bekaii-Saab on the Rationale to Evaluate Atezolizumab/Bevacizumab in MSS mCRC

October 5th 2019

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses the rationale to evaluate atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

FGFR2 Is Promising Second-Line Target in Cholangiocarcinoma

October 4th 2019

Treatment with pemigatinib resulted in a durable objective response rate in 35.5% of patients with previously treated, locally advanced or metastatic cholangiocarcinoma who harbored an FGFR2 fusion or rearrangement.

Pancreatic Cancer Is Moving Beyond the Tip of the Treatment Iceberg

October 3rd 2019

During an OncLive Peer Exchange®, a panel of pancreatic cancer experts discuss how they select between first- and subsequent-line cytotoxic regimens and strategies they use to reduce toxicity, including dose modifications and alternative combinations. They also provide insights on some of the emerging therapies in clinical trials for advanced pancreatic cancer.

Dr. Manji on Lack of Actionable Targets in Patients with Colorectal Cancer

October 2nd 2019

Gulam A. Manji, MD, PhD, discusses the importance of discovering other actionable targets for patients with colorectal cancer.

Dr. Hochster on Take-Home Message of the POLO Trial in Pancreatic Cancer

October 2nd 2019

Howard S. Hochster, MD, FACP, discusses important takeaways from the randomized, double-blind, phase III POLO trial in pancreatic cancer.

Testing Aims to Personalize Treatment, Predict Transplant Outcomes in Cholangiocarcinoma

October 2nd 2019

Lewis R. Roberts, MB, ChB, PhD, discusses the past, present, and future of treatment in patients with perihilar and intrahepatic cholangiocarcinoma.  

Dr. Mehta on TAS-102/Ramucirumab Combo Trial in Gastric/GEJ Cancer

October 2nd 2019

Rutika Mehta, MD, MPH, discusses a phase II trial that will combine ramucirumab with TAS-102 in patients with advanced gastric and gastroesophageal junction cancer.

Neoadjuvant Chemo Leads to Encouraging Resection Rates in Pancreatic Adenocarcinoma

October 2nd 2019

Davendra Sohal, MD, MPH, discusses the SWOG S1505 data and other emerging areas of research in pancreatic cancer.

Nivolumab Improves Survival in Advanced Esophageal Cancer

October 1st 2019

Nivolumab extended overall survival compared with chemotherapy in patients with previously treated advanced esophageal squamous cell carcinoma.

Dr. Djouder on the Role of Liver Regeneration in HCC

September 30th 2019

Nabil Djouder, PhD, discusses the role of liver regeneration in hepatocellular carcinoma.

Dr. Greten on the Tumor Microbiome and Antitumor Immunity in Liver Cancer

September 30th 2019

Tim F. Greten, MD, discusses the role of the gut microbiome in antitumor immunity in liver cancer.

Dr. Bekaii-Saab on the APACT Trial in Pancreatic Cancer

September 30th 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the implications of the randomized phase III APACT trial evaluating gemcitabine alone versus gemcitabine plus nab-paclitaxel as adjuvant therapy in patients with pancreatic cancer.

ClarIDHy Ivosidenib Data Practice-Changing for Advanced Cholangiocarcinoma

September 30th 2019

Treatment with ivosidenib reduced the risk of progression or death by 63% compared with placebo for pretreated patients with IDH1-mutant advanced cholangiocarcinoma.

ESMO 2019: Dr. Bekaii-Saab Highlights Important Trials in GI Malignancies

September 29th 2019